Summary

Neurovascular Devices Market Summary

The global neurovascular devices market size was estimated at USD 7.34 billion in 2024 and is projected to reach USD 11.91 billion by 2033, growing at a CAGR of 5.48% from 2025 to 2033. The market is driven by the rising prevalence of neurovascular disorders, advancements in medical technology, and an increasing focus on minimally invasive procedures.

As conditions such as stroke, cerebral aneurysms, and Arteriovenous Malformations (AVM) become more common, the demand for effective treatment options also increases. The increasing prevalence of neurovascular diseases such as strokes and aneurysms is a major driving force behind the neurovascular devices industry. Various neurovascular devices, including clot retrieval devices, microcatheters, and flow diversion coils, are utilized to treat these conditions. According to the Global Stroke Fact Sheet 2024 published by the World Stroke Organization (WSO), more than 12 million new strokes occur annually, and about 25% of the global population will experience a stroke in their lifetime.

The burden of neurovascular disorders, such as strokes, is increasing significantly, which is anticipated to propel the demand for neurovascular devices such as neurothrombectomy devices like clot retrievers and suction devices, among others.

Global Neurovascular Devices Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global neurovascular devices market report based on the device, therapeutic application, size, end-use, and region:
• Device Outlook (Revenue, USD Million, 2021 - 2033)
• Cerebral Embolization and Aneurysm Coiling Devices
o Embolic coils
o Flow diversion devices
o Liquid embolic agents
• Cerebral Angioplasty and Stenting Systems
o Carotid artery stents
o Embolic protection systems
• Neurothrombectomy Devices
o Clot retrieval devices
o Suction devices/aspiration catheters
o Vascular snares
• Support Devices
o Micro catheters
o Micro guidewires
• Trans Radial Access Devices
• Therapeutic Application Outlook (Revenue, USD Million, 2021 - 2033)
• Stroke
• Cerebral Artery
• Cerebral Aneurysm
o Aneurysmal Subarachnoid Hemorrhage
o Others
• Others
• Size (in Inches) Outlook (Revenue, USD Million, 2021 - 2033)
• 0.027"
• 0.021"
• 0.071"
• 0.017"
• 0.019"
• 0.013"
• 0.058"
• 0.068"
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Specialty Clinics
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Norway
o Denmark
o Sweden
• Asia Pacific
o Japan
o China
o India
o Australia
o South Korea
o Thailand
• Latin America
o Brazil
o Argentina
• Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o UAE
o KuwaitTable of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Device
1.2.2. Therapeutic Applications
1.2.3. Size
1.2.4. End Use
1.2.5. Regional Scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Regional outlook
2.4. Competitive Insights
Chapter 3. Neurovascular Devices Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Prevalence of Neurovascular Diseases
3.2.1.2. Technological Advancements in Neurovascular Devices
3.2.1.3. Rising Number of Awareness Initiatives
3.2.1.4. Increasing Demand for Minimally Invasive Procedures
3.2.2. Market Restraint Analysis
3.2.2.1. Product Recalls
3.2.2.2. High Treatment Cost Associated with Neurovascular Disorders
3.2.3. Market Opportunity Analysis
3.2.3.1. Growing Number of Clinical Trials
3.2.3.2. Launches of Novel Products
3.2.3.3. Increasing Research & Development Activities
3.2.4. Market Challenge Analysis
3.2.4.1. Shortage of Skilled Professionals
3.2.4.2. Potential Complications & Risks associated with Neurovascular Devices
3.3. Neurovascular Devices Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. Neurovascular Devices Market: Segment Analysis, By Device, 2021 - 2033 (USD Million)
4.1. Definition and Scope
4.2. Device Market Share Analysis, 2024 & 2033
4.3. Global Neurovascular Devices Market, by Device, 2021 to 2033
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
4.4.1. Cerebral Embolization and Aneurysm Coiling Devices
4.4.1.1. Cerebral embolization and aneurysm coiling devices market, 2021 - 2033 (USD Million)
4.4.1.2. Embolic coils
4.4.1.2.1. Embolic coils market, 2021 - 2033 (USD Million)
4.4.1.3. Flow diverters
4.4.1.3.1. Flow diverters market, 2021 - 2033 (USD Million)
4.4.1.4. Liquid embolic agents
4.4.1.4.1. Liquid embolic agents market, 2021 - 2033 (USD Million)
4.4.2. Cerebral angioplasty and stenting systems
4.4.2.1. Cerebral angioplasty and stenting systems market, 2021 - 2033 (USD Million)
4.4.2.2. Carotid Artery Stents
4.4.2.2.1. Carotid artery stents market, 2021 - 2033 (USD Million)
4.4.2.3. Embolic Protection Devices
4.4.2.3.1. Embolic protection systems devices market, 2021 - 2033 (USD Million)
4.4.3. Neurothrombectomy devices
4.4.3.1. Neurothrombectomy devices market, 2021 - 2033 (USD Million)
4.4.3.2. Clot Retrieval Devices
4.4.3.2.1. Clot retrieval devices market, 2021 - 2033 (USD Million)
4.4.3.3. Suction Devices
4.4.3.3.1. Suction devices market, 2021 - 2033 (USD Million)
4.4.3.4. Vascular Snares
4.4.3.4.1. Vascular snares market, 2021 - 2033 (USD Million)
4.4.4. Support devices
4.4.4.1. Support devices market, 2021 - 2033 (USD Million)
4.4.4.2. Micro Catheters
4.4.4.2.1. Micro catheters market, 2021 - 2033 (USD Million)
4.4.4.3. Micro Guidewires
4.4.4.3.1. Micro guidewires market, 2021 - 2033 (USD Million)
4.4.5. Trans Radial Access Devices
4.4.5.1. Trans radial access devices market, 2021 - 2033 (USD Million)
Chapter 5. Neurovascular Devices Market: Segment Analysis, By Therapeutic Applications, 2021 - 2033 (USD Million)
5.1. Definition and Scope
5.2. Therapeutic Applications Market Share Analysis, 2024 & 2033
5.3. Global Neurovascular Devices Market, by Therapeutic Applications, 2021 to 2033
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
5.4.1. Stroke
5.4.1.1. Stroke market, 2021 - 2033 (USD Million)
5.4.2. Cerebral artery stenosis
5.4.2.1. Cerebral artery stenosis market, 2021 - 2033 (USD Million)
5.4.3. Cerebral aneurysm
5.4.3.1. Cerebral aneurysm market, 2021 - 2033 (USD Million)
5.4.3.2. Aneurysmal Subarachnoid Hemorrhage
5.4.3.2.1. Aneurysmal subarachnoid hemorrhage market, 2021 - 2033 (USD Million)
5.4.3.3. Others
5.4.3.4. Others market, 2021 - 2033 (USD Million)
5.4.4. Others
5.4.4.1. Others market, 2021 - 2033 (USD Million)
Chapter 6. Neurovascular Devices Market: Segment Analysis, By Size, 2021 - 2033 (USD Million)
6.1. Definition and Scope
6.2. Size Market Share Analysis, 2024 & 2033
6.3. Global Neurovascular Devices Market, by Size, 2021 to 2033
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
6.4.1. 0.027"
6.4.1.1. 0.027" market, 2021 - 2033 (USD Million)
6.4.2. 0.021"
6.4.2.1. 0.021" market, 2021 - 2033 (USD Million)
6.4.3. 0.071"
6.4.3.1. 0.071" market, 2021 - 2033 (USD Million)
6.4.4. 0.017"
6.4.4.1. 0.017" market, 2021 - 2033 (USD Million)
6.4.5. 0.019"
6.4.5.1. 0.019" market, 2021 - 2033 (USD Million)
6.4.6. 0.013"
6.4.6.1. 0.013" market, 2021 - 2033 (USD Million)
6.4.7. 0.058"
6.4.7.1. 0.058" market, 2021 - 2033 (USD Million)
6.4.8. 0.068"
6.4.8.1. 0.068" market, 2021 - 2033 (USD Million)
6.4.9. Others
6.4.9.1. Others market, 2021 - 2033 (USD Million)
Chapter 7. Neurovascular Devices Market: Segment Analysis, By End Use, 2021 - 2033 (USD Million)
7.1. Definition and Scope
7.2. End Use Market Share Analysis, 2024 & 2033
7.3. Global Neurovascular Devices Market, by End Use, 2021 to 2033
7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
7.4.1. Hospital
7.4.1.1. Hospital market, 2021 - 2033 (USD Million)
7.4.2. Specialty clinics
7.4.2.1. Specialty clinics market, 2021 - 2033 (USD Million)
7.4.3. Others
7.4.3.1. Others market, 2021 - 2033 (USD Million)
Chapter 8. Neurovascular Devices Market: Regional Estimates & Trend Analysis
8.1. Regional Dashboard
8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework/ reimbursement structure
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts 2021 to 2033, (USD Million)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework/ reimbursement structure
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts 2021 to 2033, (USD Million)
8.3.3. Mexico
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework/ reimbursement structure
8.3.3.3. Competitive scenario
8.3.3.4. Mexico market estimates and forecasts 2021 to 2033, (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/ reimbursement structure
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts 2021 to 2033, (USD Million)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/ reimbursement structure
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts 2021 to 2033, (USD Million)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework/ reimbursement structure
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts 2021 to 2033, (USD Million)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework/ reimbursement structure
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts 2021 to 2033, (USD Million)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework/ reimbursement structure
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts 2021 to 2033, (USD Million)
8.4.6. Norway
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework/ reimbursement structure
8.4.6.3. Competitive scenario
8.4.6.4. Norway market estimates and forecasts 2021 to 2033, (USD Million)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework/ reimbursement structure
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts 2021 to 2033, (USD Million)
8.4.8. Denmark
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework/ reimbursement structure
8.4.8.3. Competitive scenario
8.4.8.4. Denmark market estimates and forecasts 2021 to 2033, (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts 2021 to 2033, (USD Million)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts 2021 to 2033, (USD Million)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts 2021 to 2033, (USD Million)
8.5.4. Australia
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework/ reimbursement structure
8.5.4.3. Competitive scenario
8.5.4.4. Australia market estimates and forecasts 2021 to 2033, (USD Million)
8.5.5. South Korea
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework/ reimbursement structure
8.5.5.3. Competitive scenario
8.5.5.4. South Korea market estimates and forecasts 2021 to 2033, (USD Million)
8.5.6. Thailand
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework/ reimbursement structure
8.5.6.3. Competitive scenario
8.5.6.4. Thailand market estimates and forecasts 2021 to 2033, (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts 2021 to 2033, (USD Million)
8.6.2. Argentina
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Argentina market estimates and forecasts 2021 to 2033, (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts 2021 to 2033, (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033, (USD Million)
8.7.3. UAE
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. UAE market estimates and forecasts 2021 to 2033, (USD Million)
8.7.4. Kuwait
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033, (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Innovators
9.4. Vendor Landscape
9.5. List of key distributors and channel partners
9.6. Key customers
9.7. Global Key company market share analysis, 2024
9.7.1. Medtronic
9.7.1.1. Company overview
9.7.1.2. Financial performance
9.7.1.3. Product benchmarking
9.7.1.4. Strategic initiatives
9.7.2. Stryker
9.7.2.1. Company overview
9.7.2.2. Financial performance
9.7.2.3. Product benchmarking
9.7.2.4. Strategic initiatives
9.7.3. Terumo Corporation
9.7.3.1. Company overview
9.7.3.2. Financial performance
9.7.3.3. Product benchmarking
9.7.3.4. Strategic initiatives
9.7.4. Penumbra, Inc.
9.7.4.1. Company overview
9.7.4.2. Financial performance
9.7.4.3. Product benchmarking
9.7.4.4. Strategic initiatives
9.7.5. Johnson & Johnson and its affiliates
9.7.5.1. Company overview
9.7.5.2. Financial performance
9.7.5.3. Product benchmarking
9.7.5.4. Strategic initiatives
9.7.6. MicroPort Scientific Corporation
9.7.6.1. Company overview
9.7.6.2. Financial performance
9.7.6.3. Product benchmarking
9.7.6.4. Strategic initiatives
9.7.7. Acandis GmbH
9.7.7.1. Company overview
9.7.7.2. Financial performance
9.7.7.3. Product benchmarking
9.7.7.4. Strategic initiatives
9.7.8. ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
9.7.8.1. Company overview
9.7.8.2. Financial performance
9.7.8.3. Product benchmarking
9.7.8.4. Strategic initiatives
9.7.9. NeuroSafe Medical Co., Ltd.
9.7.9.1. Company overview
9.7.9.2. Financial performance
9.7.9.3. Product benchmarking
9.7.9.4. Strategic initiatives
9.7.10. Rapid Medical
9.7.10.1. Company overview
9.7.10.2. Financial performance
9.7.10.3. Product benchmarking
9.7.10.4. Strategic initiatives
9.7.11. Evasc Neurovascular Enterprises
9.7.11.1. Company overview
9.7.11.2. Financial performance
9.7.11.3. Product benchmarking
9.7.11.4. Strategic initiatives
9.7.12. Lepu Medical Technology(Beijing)Co., Ltd.
9.7.12.1. Company overview
9.7.12.2. Financial performance
9.7.12.3. Product benchmarking
9.7.12.4. Strategic initiatives
9.7.13. phenox GmbH
9.7.13.1. Company overview
9.7.13.2. Financial performance
9.7.13.3. Product benchmarking
9.7.13.4. Strategic initiatives
9.8. Heat Map Analysis/ Company Market Position Analysis
9.9. Estimated Company Market Share Analysis, 2024
9.10. List of Other Key Market Players

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Device
1.2.2. Therapeutic Applications
1.2.3. Size
1.2.4. End Use
1.2.5. Regional Scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Regional outlook
2.4. Competitive Insights
Chapter 3. Neurovascular Devices Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Prevalence of Neurovascular Diseases
3.2.1.2. Technological Advancements in Neurovascular Devices
3.2.1.3. Rising Number of Awareness Initiatives
3.2.1.4. Increasing Demand for Minimally Invasive Procedures
3.2.2. Market Restraint Analysis
3.2.2.1. Product Recalls
3.2.2.2. High Treatment Cost Associated with Neurovascular Disorders
3.2.3. Market Opportunity Analysis
3.2.3.1. Growing Number of Clinical Trials
3.2.3.2. Launches of Novel Products
3.2.3.3. Increasing Research & Development Activities
3.2.4. Market Challenge Analysis
3.2.4.1. Shortage of Skilled Professionals
3.2.4.2. Potential Complications & Risks associated with Neurovascular Devices
3.3. Neurovascular Devices Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. Neurovascular Devices Market: Segment Analysis, By Device, 2021 - 2033 (USD Million)
4.1. Definition and Scope
4.2. Device Market Share Analysis, 2024 & 2033
4.3. Global Neurovascular Devices Market, by Device, 2021 to 2033
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
4.4.1. Cerebral Embolization and Aneurysm Coiling Devices
4.4.1.1. Cerebral embolization and aneurysm coiling devices market, 2021 - 2033 (USD Million)
4.4.1.2. Embolic coils
4.4.1.2.1. Embolic coils market, 2021 - 2033 (USD Million)
4.4.1.3. Flow diverters
4.4.1.3.1. Flow diverters market, 2021 - 2033 (USD Million)
4.4.1.4. Liquid embolic agents
4.4.1.4.1. Liquid embolic agents market, 2021 - 2033 (USD Million)
4.4.2. Cerebral angioplasty and stenting systems
4.4.2.1. Cerebral angioplasty and stenting systems market, 2021 - 2033 (USD Million)
4.4.2.2. Carotid Artery Stents
4.4.2.2.1. Carotid artery stents market, 2021 - 2033 (USD Million)
4.4.2.3. Embolic Protection Devices
4.4.2.3.1. Embolic protection systems devices market, 2021 - 2033 (USD Million)
4.4.3. Neurothrombectomy devices
4.4.3.1. Neurothrombectomy devices market, 2021 - 2033 (USD Million)
4.4.3.2. Clot Retrieval Devices
4.4.3.2.1. Clot retrieval devices market, 2021 - 2033 (USD Million)
4.4.3.3. Suction Devices
4.4.3.3.1. Suction devices market, 2021 - 2033 (USD Million)
4.4.3.4. Vascular Snares
4.4.3.4.1. Vascular snares market, 2021 - 2033 (USD Million)
4.4.4. Support devices
4.4.4.1. Support devices market, 2021 - 2033 (USD Million)
4.4.4.2. Micro Catheters
4.4.4.2.1. Micro catheters market, 2021 - 2033 (USD Million)
4.4.4.3. Micro Guidewires
4.4.4.3.1. Micro guidewires market, 2021 - 2033 (USD Million)
4.4.5. Trans Radial Access Devices
4.4.5.1. Trans radial access devices market, 2021 - 2033 (USD Million)
Chapter 5. Neurovascular Devices Market: Segment Analysis, By Therapeutic Applications, 2021 - 2033 (USD Million)
5.1. Definition and Scope
5.2. Therapeutic Applications Market Share Analysis, 2024 & 2033
5.3. Global Neurovascular Devices Market, by Therapeutic Applications, 2021 to 2033
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
5.4.1. Stroke
5.4.1.1. Stroke market, 2021 - 2033 (USD Million)
5.4.2. Cerebral artery stenosis
5.4.2.1. Cerebral artery stenosis market, 2021 - 2033 (USD Million)
5.4.3. Cerebral aneurysm
5.4.3.1. Cerebral aneurysm market, 2021 - 2033 (USD Million)
5.4.3.2. Aneurysmal Subarachnoid Hemorrhage
5.4.3.2.1. Aneurysmal subarachnoid hemorrhage market, 2021 - 2033 (USD Million)
5.4.3.3. Others
5.4.3.4. Others market, 2021 - 2033 (USD Million)
5.4.4. Others
5.4.4.1. Others market, 2021 - 2033 (USD Million)
Chapter 6. Neurovascular Devices Market: Segment Analysis, By Size, 2021 - 2033 (USD Million)
6.1. Definition and Scope
6.2. Size Market Share Analysis, 2024 & 2033
6.3. Global Neurovascular Devices Market, by Size, 2021 to 2033
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
6.4.1. 0.027"
6.4.1.1. 0.027" market, 2021 - 2033 (USD Million)
6.4.2. 0.021"
6.4.2.1. 0.021" market, 2021 - 2033 (USD Million)
6.4.3. 0.071"
6.4.3.1. 0.071" market, 2021 - 2033 (USD Million)
6.4.4. 0.017"
6.4.4.1. 0.017" market, 2021 - 2033 (USD Million)
6.4.5. 0.019"
6.4.5.1. 0.019" market, 2021 - 2033 (USD Million)
6.4.6. 0.013"
6.4.6.1. 0.013" market, 2021 - 2033 (USD Million)
6.4.7. 0.058"
6.4.7.1. 0.058" market, 2021 - 2033 (USD Million)
6.4.8. 0.068"
6.4.8.1. 0.068" market, 2021 - 2033 (USD Million)
6.4.9. Others
6.4.9.1. Others market, 2021 - 2033 (USD Million)
Chapter 7. Neurovascular Devices Market: Segment Analysis, By End Use, 2021 - 2033 (USD Million)
7.1. Definition and Scope
7.2. End Use Market Share Analysis, 2024 & 2033
7.3. Global Neurovascular Devices Market, by End Use, 2021 to 2033
7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
7.4.1. Hospital
7.4.1.1. Hospital market, 2021 - 2033 (USD Million)
7.4.2. Specialty clinics
7.4.2.1. Specialty clinics market, 2021 - 2033 (USD Million)
7.4.3. Others
7.4.3.1. Others market, 2021 - 2033 (USD Million)
Chapter 8. Neurovascular Devices Market: Regional Estimates & Trend Analysis
8.1. Regional Dashboard
8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework/ reimbursement structure
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts 2021 to 2033, (USD Million)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework/ reimbursement structure
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts 2021 to 2033, (USD Million)
8.3.3. Mexico
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework/ reimbursement structure
8.3.3.3. Competitive scenario
8.3.3.4. Mexico market estimates and forecasts 2021 to 2033, (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/ reimbursement structure
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts 2021 to 2033, (USD Million)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/ reimbursement structure
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts 2021 to 2033, (USD Million)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework/ reimbursement structure
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts 2021 to 2033, (USD Million)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework/ reimbursement structure
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts 2021 to 2033, (USD Million)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework/ reimbursement structure
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts 2021 to 2033, (USD Million)
8.4.6. Norway
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework/ reimbursement structure
8.4.6.3. Competitive scenario
8.4.6.4. Norway market estimates and forecasts 2021 to 2033, (USD Million)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework/ reimbursement structure
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts 2021 to 2033, (USD Million)
8.4.8. Denmark
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework/ reimbursement structure
8.4.8.3. Competitive scenario
8.4.8.4. Denmark market estimates and forecasts 2021 to 2033, (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts 2021 to 2033, (USD Million)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts 2021 to 2033, (USD Million)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts 2021 to 2033, (USD Million)
8.5.4. Australia
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework/ reimbursement structure
8.5.4.3. Competitive scenario
8.5.4.4. Australia market estimates and forecasts 2021 to 2033, (USD Million)
8.5.5. South Korea
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework/ reimbursement structure
8.5.5.3. Competitive scenario
8.5.5.4. South Korea market estimates and forecasts 2021 to 2033, (USD Million)
8.5.6. Thailand
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework/ reimbursement structure
8.5.6.3. Competitive scenario
8.5.6.4. Thailand market estimates and forecasts 2021 to 2033, (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts 2021 to 2033, (USD Million)
8.6.2. Argentina
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Argentina market estimates and forecasts 2021 to 2033, (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts 2021 to 2033, (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033, (USD Million)
8.7.3. UAE
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. UAE market estimates and forecasts 2021 to 2033, (USD Million)
8.7.4. Kuwait
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033, (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Innovators
9.4. Vendor Landscape
9.5. List of key distributors and channel partners
9.6. Key customers
9.7. Global Key company market share analysis, 2024
9.7.1. Medtronic
9.7.1.1. Company overview
9.7.1.2. Financial performance
9.7.1.3. Product benchmarking
9.7.1.4. Strategic initiatives
9.7.2. Stryker
9.7.2.1. Company overview
9.7.2.2. Financial performance
9.7.2.3. Product benchmarking
9.7.2.4. Strategic initiatives
9.7.3. Terumo Corporation
9.7.3.1. Company overview
9.7.3.2. Financial performance
9.7.3.3. Product benchmarking
9.7.3.4. Strategic initiatives
9.7.4. Penumbra, Inc.
9.7.4.1. Company overview
9.7.4.2. Financial performance
9.7.4.3. Product benchmarking
9.7.4.4. Strategic initiatives
9.7.5. Johnson & Johnson and its affiliates
9.7.5.1. Company overview
9.7.5.2. Financial performance
9.7.5.3. Product benchmarking
9.7.5.4. Strategic initiatives
9.7.6. MicroPort Scientific Corporation
9.7.6.1. Company overview
9.7.6.2. Financial performance
9.7.6.3. Product benchmarking
9.7.6.4. Strategic initiatives
9.7.7. Acandis GmbH
9.7.7.1. Company overview
9.7.7.2. Financial performance
9.7.7.3. Product benchmarking
9.7.7.4. Strategic initiatives
9.7.8. ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
9.7.8.1. Company overview
9.7.8.2. Financial performance
9.7.8.3. Product benchmarking
9.7.8.4. Strategic initiatives
9.7.9. NeuroSafe Medical Co., Ltd.
9.7.9.1. Company overview
9.7.9.2. Financial performance
9.7.9.3. Product benchmarking
9.7.9.4. Strategic initiatives
9.7.10. Rapid Medical
9.7.10.1. Company overview
9.7.10.2. Financial performance
9.7.10.3. Product benchmarking
9.7.10.4. Strategic initiatives
9.7.11. Evasc Neurovascular Enterprises
9.7.11.1. Company overview
9.7.11.2. Financial performance
9.7.11.3. Product benchmarking
9.7.11.4. Strategic initiatives
9.7.12. Lepu Medical Technology(Beijing)Co., Ltd.
9.7.12.1. Company overview
9.7.12.2. Financial performance
9.7.12.3. Product benchmarking
9.7.12.4. Strategic initiatives
9.7.13. phenox GmbH
9.7.13.1. Company overview
9.7.13.2. Financial performance
9.7.13.3. Product benchmarking
9.7.13.4. Strategic initiatives
9.8. Heat Map Analysis/ Company Market Position Analysis
9.9. Estimated Company Market Share Analysis, 2024
9.10. List of Other Key Market Players